About
Who we are
Mission & commitment
Leadership
Investors & partners
Contact
Science
SH2-targeted therapies
Platform
Pipeline
Overview
REX-8756
(STAT6 inhibitor)
BTK inhibitor
Patients
Our commitment
Clinical trials
Role of STAT6
News & Events
Highlights
Press releases
Events & presentations
Careers
Culture & values
Benefits
Job openings
Team
Go Back
News: REX-8756 Phase 1 Milestone
×
Previous
Next
MENU
About
Who we are
Mission & commitment
Leadership
Investors & partners
Contact
Science
SH2-targeted therapies
Platform
Pipeline
Overview
REX-8756
(STAT6 inhibitor)
BTK inhibitor
Patients
Our commitment
Clinical trials
Role of STAT6
News & Events
Highlights
Press releases
Events & presentations
Careers
Culture & values
Benefits
Job openings
